Last Updated: June 17, 2026
By: Brian Karr · Co-Founder & Chief Inspection Officer, We Inspect
Most treatment of mold illness plateaus or fails entirely because the environmental trigger is still present. Step one of the Shoemaker Protocol is removal from exposure — not pharmaceutical intervention. Until the contamination driving your illness is found and documented at its source, every treatment step downstream is working against an active, ongoing exposure.
Chronic Inflammatory Response Syndrome (CIRS) is a biotoxin-mediated, multisystem inflammatory illness triggered by exposure to water-damaged buildings, mold, and the mycotoxins they produce. In genetically susceptible individuals (estimated at roughly 24–25% of the general population), the immune system cannot properly clear these biotoxins, driving a sustained inflammatory cascade that affects cognitive function, energy, hormonal regulation, and immune activity all at once.1
If you’ve been working with a CIRS-literate clinician, you may recognize the pattern: lab markers are elevated, a protocol has started, but the numbers aren’t moving. For background on the condition itself, see our guide to the 17 signs of mold illness. This article covers what proper source identification requires — and why most current approaches miss it.
Key Takeaways
- The Shoemaker Protocol’s first step is removal from the exposure environment. Treatment cannot properly sequence without it.
- Air testing and ERMI routinely miss active mold growth because mold develops inside building cavities, not primarily in living space air.
- Source-level Exposure Mapping™ identifies where active growth is occurring today, giving clinicians and contractors the location-specific data they need to act.
- CIRS biomarkers can normalize with properly sequenced treatment — and that recovery requires finding and removing the source first.
- If symptoms improve consistently when away from home and worsen on return, the environmental source may still be active.
What the Shoemaker Protocol Actually Requires
The Shoemaker Protocol runs eleven sequential steps, each built on the one before it. And step one is always removal from the exposure environment. Binders, VIP (vasoactive intestinal peptide), and MARCONS treatment come later. None of them can do their job until step one is complete.
The protocol is built on a biological premise: if biotoxins are still entering the body, the downstream steps cannot achieve their intended effect. Cholestyramine and other binders intercept biotoxins in the gut, but they can’t outpace a continuous active source. VIP normalizes gene expression, but that normalization doesn’t hold while the triggering exposure persists.
A 2024 systematic review in Annals of Medicine and Surgery evaluated thirteen published CIRS treatment studies and found that the Shoemaker Protocol is the only documented treatment framework that produces biomarker normalization in CIRS patients, not just symptom reduction.2 Every study in that review showing lasting biomarker improvement involved verified source removal as a precondition. That’s not a technicality. It’s the mechanism the entire protocol is built on.
For a complete picture of what CIRS is and how it develops, see What Is CIRS? Chronic Inflammatory Response Syndrome Explained.
Why CIRS Treatment Keeps Stalling
I hear a version of the same situation almost every month on consultation calls. A man in Denver reached out last spring after nine months on the Shoemaker Protocol — cholestyramine, intranasal VIP, the full sequence — with C4a levels that had barely shifted. His functional medicine doctor was stumped. An ERMI had come back low. Nobody had looked inside the walls where the HVAC ducting met the basement slab. That’s where we found active Chaetomium and Stachybotrys, both producers of trichothecenes that rank among the most potent mycotoxins found in residential buildings.
The ERMI missed it because ERMI measures mold species abundance in settled dust. It doesn’t identify where active growth is occurring today. His body was still absorbing mycotoxins from a source no one had found.
Research published in Toxins documented that 93% of chronic fatigue syndrome patients with water-damaged building histories tested positive for measurable mycotoxins in urine, with trichothecenes detected in 58% of cases.3 That body burden doesn’t resolve on its own. It requires eliminating the source. A mold illness treatment protocol, however well designed, works against that burden rather than alongside it when exposure continues. The numbers can’t move in a meaningful direction when the source tap is still running.
This is closely tied to how biotoxins drive the CIRS cascade in the first place. For more, see Mold Biotoxin Illness: Understanding the Root Cause.
Why Most Sources Stay Hidden
The default mold test in most homes is an air sample. A professional draws air from a few rooms, a lab measures spore counts, and if the numbers fall within normal range, the building gets a clean result. Many families spend thousands on this kind of testing and receive a reassuring report while their exposure pattern remains entirely intact.
There’s a fundamental problem. Mold grows inside building cavities, not in the living space air. Active growth happens in wall assemblies, under flooring, inside HVAC components, behind shower enclosures. Spore counts in room air don’t accurately reflect what’s happening in those locations, particularly when HVAC systems are filtering the air and construction barriers are containing the growth physically.
A 2013 review in The Scientific World Journal documented that trichothecene inhalation is approximately 20 times more toxic than other exposure routes.4 The question isn’t whether spore counts are high. It’s whether the right kind of source is present at all. Air sampling can’t answer that.
| Testing Method | What It Detects | Key Limitation for CIRS | Clinical Value |
|---|---|---|---|
| Air sampling (spore trap) | Airborne spore counts in room air | Active growth is typically inside cavities; room air counts are often low even with an active source nearby | Limited — can completely miss the active source driving CIRS |
| ERMI (settled dust) | Mold species relative abundance in settled dust | Reflects historical accumulation, not active growth location; does not measure mycotoxins | Partial — historical exposure context only, not an active source map |
| Source-level sampling | Active growth at building envelope locations | Requires physical access to the likely growth sites | High — identifies active source, provides location-specific remediation scope |
For more on how CIRS biomarker testing connects to environmental documentation, see CIRS Testing: What to Ask Your Doctor.
What Exposure Mapping Actually Finds
We Inspect’s Exposure Mapping™ process doesn’t sample the air. It samples the building envelope: the physical locations where moisture intrusion, temperature differentials, and construction failures create conditions for active fungal growth.
The distinction matters clinically. ERMI testing, which many CIRS patients have already completed, provides information about cumulative historical mold exposure in a home. It cannot identify where active growth is occurring right now, and it doesn’t measure mycotoxins at all. Mycotoxin dust sampling is a separate test entirely, with different methodology and different clinical interpretation. Conflating these produces a false sense that the environment has been properly characterized when it hasn’t.
Source-level sampling maps physical locations: specific wall assemblies, sub-floor cavities, HVAC coil compartments, attic-to-living-space penetration points. A 2013 review in The Scientific World Journal found that 27 of 28 mold-illness patients returned to work following treatment that included verified source removal — a concrete outcome that puts the difference between treating symptoms and eliminating the source in practical terms.4
When we identify active Stachybotrys inside a wall cavity that produces clean air at the surface, that finding changes the treatment trajectory. The clinician has a documented environmental source. The contractor has a location-specific scope. And the patient finally has a coherent explanation for why the protocol wasn’t working.
What Recovery From CIRS Actually Requires
The clinical case for recovery is documented in peer-reviewed research. A 2016 study in Medical Research Archives used RNA-Seq analysis to map genome-wide changes in white blood cell function before and after treatment in CIRS patients, finding that CIRS biomarkers can normalize with properly sequenced treatment.5 The molecular hypometabolism that characterizes untreated CIRS (measurable suppression of cellular energy production) reversed with appropriate intervention. That’s biological normalization, not symptom management.
The 2024 review in Annals of Medicine and Surgery noted that across all evaluated studies, return-to-function outcomes were documented when the environmental source and the downstream inflammatory cascade were addressed together.2 One person described what that recovery felt like during a consultation call:
“I couldn’t walk from one room to the next. I was so bad before. And now I can walk — back to being much more of a normal person.”
That recovery didn’t happen on binders alone. It happened after the source was identified, the environment changed, and the protocol could work without competing against an ongoing exposure. For a closer look at recovery timelines and what the process actually looks like, see Can CIRS Be Cured? What Recovery Actually Looks Like.
Signs Your Exposure May Still Be Active
If treatment is stalling, the most important question isn’t which binder to switch to. It’s whether you’re still being exposed to the source that triggered this.
Some patterns are clinically diagnostic. Symptoms that are consistently worse at home and better within days of leaving: vacation, a work trip, staying with family. Symptoms that improved over summer and came back in fall and winter, when more time is spent inside with the HVAC running. Many families describe this retrospectively. “I start looking back at those good times, and I’m like, oh, well, we were outside more, it was summertime, or we weren’t home — you start realizing you’re away from the house and things are better.”
Rinne and Tuuminen’s 2017 longitudinal cohort study in Frontiers in Immunology followed 80+ individuals exposed to a mold-contaminated building and documented progressive health deterioration over time, including elevated rates of autoimmune conditions in those who remained exposed without intervention.6 The natural course of untreated mold illness is not stable. It progresses.
A 2024 case series in Mycotoxin Research confirmed that HLA haplotype directly determines the severity of mycotoxin-induced illness.7 Two people in the same building can have completely different health trajectories based on their genetic susceptibility alone. This explains why one family member becomes severely ill while another feels relatively fine — and why the person who is sick can’t simply “tough it out” while the source remains present.
The other signal is remediation that didn’t hold. The phrase I hear regularly: “I thought the issue we knew of was taken care of.” Surface remediation (addressing visible mold without identifying the active growth site) leaves the source in place. Testing that doesn’t reach the building envelope can return the same false all-clear. If symptoms returned or never fully resolved after remediation, source removal may not have been complete.
Key Takeaways
- The Shoemaker Protocol’s first step is removal from the exposure environment. Treatment cannot properly sequence without it.
- Air testing and ERMI routinely miss active mold growth because mold develops inside building cavities, not primarily in living space air.
- Source-level Exposure Mapping™ identifies where active growth is occurring today, giving clinicians and contractors the location-specific data they need to act.
- CIRS biomarkers can normalize with properly sequenced treatment — and that recovery requires finding and removing the source first.
- If symptoms improve consistently when away from home and worsen on return, the environmental source may still be active.
The pattern we see consistently: treatment stalls not because the protocol is wrong, but because the environment causing the problem hasn’t been properly identified. A Shoemaker Protocol mold illness treatment framework is a tool. And like any tool, it performs well only when the conditions it requires are in place.
Source removal isn’t one consideration among several. It’s the first step — the one everything else is built on. Finding that source, specifically and accurately, is what separates treatment that works from treatment that cycles through protocols without resolution.
If you’ve been in that cycle, the next question isn’t about the protocol. It’s about what’s still in the building.
Next Steps
If you want to know what your home is actually doing to your body, we can find out. We Inspect uncovers hidden mold contamination through source-level exposure mapping, ranks what truly drives your exposure, and delivers a contractor-ready Remediation Recovery Blueprint designed to meaningfully reduce exposure so your body can heal — without wasting tens of thousands on fixes that won’t move the needle. Get My Free Exposure Consultation
Frequently Asked Questions
What is step one of the Shoemaker Protocol for CIRS treatment?
Step one of the Shoemaker Protocol is removal from the exposure environment — the water-damaged building or mold source triggering biotoxin illness. No subsequent treatment step (binders, VIP, MARCONS treatment) can achieve its intended effect while active biotoxin exposure continues. Every published study showing lasting biomarker normalization involved verified source removal as a precondition.
Can CIRS be treated while still living in a home with mold?
Some clinicians attempt treatment while patients remain in the home, particularly when relocation isn’t feasible. The evidence consistently shows, however, that biomarker normalization is significantly harder to achieve while exposure continues. At minimum, identifying and remediating the active growth site is required for treatment to progress meaningfully rather than stall or cycle.
Why did my ERMI come back low if I’m still getting sick from mold?
ERMI measures mold species relative abundance in settled dust, reflecting historical accumulation rather than active growth. A low ERMI score doesn’t rule out an active mold source in wall cavities, HVAC components, or sub-floor assemblies physically separated from the living space. ERMI also doesn’t measure mycotoxins. Source-level sampling at likely growth sites is needed to rule that out.
How do I know if mold is still present after remediation?
The clearest indicator is a symptom pattern tied to location: worse at home, better within days of leaving. Symptoms that improved briefly after remediation and then returned may indicate incomplete source removal or a secondary source not addressed in the original scope. Source-level re-sampling at known and adjacent locations can confirm whether active growth persists.
What mold species are most relevant to CIRS?
Stachybotrys chartarum and Chaetomium species are most commonly associated with the trichothecene mycotoxins implicated in CIRS. Aspergillus and Penicillium species produce ochratoxin A and gliotoxin. All grow in water-damaged building materials and are typically found inside construction cavities rather than in detectable concentrations in living space air.
Can you recover from CIRS completely?
Clinical research and documented patient outcomes support meaningful recovery from CIRS, including biomarker normalization, when treatment is properly sequenced and the environmental source is removed. Recovery timelines vary based on duration of exposure, HLA haplotype, and how early intervention begins. Many patients experience significant functional improvement within months of confirmed source removal and protocol initiation.
Does a mold illness treatment protocol work the same for genetically susceptible people?
Roughly 24–25% of the population carries HLA haplotypes that prevent effective biotoxin clearance, making them significantly more reactive to mold exposure. For this group, the Shoemaker Protocol applies — but source removal becomes even more critical, because these individuals cannot compensate for ongoing exposure the way genetically typical people sometimes can. Identifying the source is the non-negotiable prerequisite.
References
- Rao TR, Sravya G, Kaushik T, Akshaya D. Chronic Inflammatory Response Syndrome (CIRS): A Review of Diagnosis, Immunological Mechanisms and Treatment Challenges. International Journal of Creative and Systematic Research and Reviews. 2025;8(7). doi:10.47191/ijcsrr/v8-i7-09
- Dooley M, Vukelic A, Jim L. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment. Annals of Medicine and Surgery. 2024. doi:10.1097/MS9.0000000000002718
- Brewer JH, et al. Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome. Toxins. 2013;5(4):605–617. doi:10.3390/toxins5040605
- Hope J. A Review of the Mechanism of Injury and Treatment Approaches for Illness Resulting from Exposure to Water-Damaged Buildings, Mold, and Mycotoxins. The Scientific World Journal. 2013;2013:767482. doi:10.1155/2013/767482
- Shoemaker RC. RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal peptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing. Medical Research Archives. 2016;4(7). doi:10.18103/MRA.V4I7.862
- Rinne K, Tuuminen T. Severe Sequelae to Mold-Related Illness as Demonstrated in Two Finnish Cohorts. Frontiers in Immunology. 2017;8:382. doi:10.3389/fimmu.2017.00382
- Saghir S, Ansari RA. HLA gene variations and mycotoxin toxicity: Four case reports. Mycotoxin Research. 2024;40:57–68. doi:10.1007/s12550-023-00517-y
This article is for informational purposes only and does not constitute professional medical advice. If you believe mold or other environmental hazards may be affecting your health, consult your healthcare provider.